How Omicron Affects Testing for the Coronavirus
(Bloomberg) -- The rise of the omicron variant of the coronavirus has refocused attention on the importance of testing as a tool for bringing the pandemic under control -- and keeping it that way. At the same time, some tests used to identify infections may be less accurate detecting omicron cases.
1. How has omicron affected test performance?
The U.S. Food and Drug Administration has notified health care professionals of a handful of tests that, in the absence of modifications, are expected to fail to detect the variant or that were modified in order to pick it up. These are all so-called molecular tests, the gold-standard for diagnosing a coronavirus infection. The FDA said Dec. 28 that early data suggest that antigen tests -- which are faster, cheaper and more accessible -- detect omicron but possibly with reduced accuracy. A study posted Dec. 24 suggested that saliva samples may be better for diagnosing omicron than nasal specimens, whereas the opposite was true for delta, the variant that became the dominant strain worldwide in mid-2021.
2. What if I get a negative result with an antigen test?
If you're experiencing symptoms of Covid or have a high likelihood of infection due to exposure to the coronavirus, the FDA recommends following up with a molecular test. Even before omicron emerged, it was clear that antigen tests are generally less likely to pick up early infections than molecular tests. In a small study posted Jan. 5, among 30 people who became infected during omicron waves in the U.S. and received both types of tests, the median time was three days from a first positive on a molecular test to a positive on an antigen test. In four cases, individuals were confirmed to have spread the virus to someone else after receiving false negatives on antigen tests.
3. How do the tests differ?
Both look for the presence of the coronavirus in your nose, throat or mouth, but they do so in different ways. Molecular tests seek bits of the virus's nucleic acids, or its genetic material, in a sample of secretions. Antigen tests search out proteins on the surface of the virus.
4. Why not just rely on molecular tests?
Molecular tests typically require several components, including chemical reagents, small plastic containers and swabs. One widely used type relies on trained lab technicians to perform a complicated process called reverse transcription polymerase chain reaction (RT-PCR), which amplifies the virus's genetic material so that it can be studied in detail. A lack of components, machinery or technicians can limit the availability of these tests. While some molecular tests can churn out results in 30 minutes or less, they don't scale very well. Thus, countries have increasingly embraced antigen tests, some of which people can perform at home. One version of an antigen test is called a lateral flow test. Similar to a home pregnancy test, it runs a liquid sample over a reactive surface.
5. What are the benefits of antigen tests?
Advocates of antigen tests argue that, while they'll probably never be as sensitive as molecular tests, they compensate for that with their speed and accessibility. In a pilot study in Liverpool, England, in late 2020, rapid antigen tests identified nearly 900 people who didn't realize they had a coronavirus infection -- and presumably wouldn't have otherwise gotten tested. For these tests to function best, people may need to perform them regularly.
6. How do we keep track of variants?
The best way to identify new variants of concern and monitor their spread is to take samples from infected people and sequence the genome of the entire virus or at least the spike protein that gives it its crown-like appearance. That, however, can be expensive and time-consuming. As a shortcut, researchers use other techniques, such as subjecting samples to molecular tests that have been slightly tweaked to identify specific mutations. That helps get a faster and fuller picture of what virus strains are fueling a region's outbreak, though it's important for researchers to confirm some of those results with genetic sequencing.
7. What other type of coronavirus tests exist?
Another type, generally a blood test, measures how much -- if any -- immunity a person has against the virus, either from a previous infection or from a vaccination. A person infected by a virus or vaccinated against it summons, among other tools of the immune system, antibodies designed specifically, like keys for a particular door, to latch onto and neutralize the proteins that form the bulk of that particular virus. These antibodies can linger for months -- or even years in some cases -- though their levels tend to fall over time, a key factor behind vaccine booster campaigns. If a person has already fought off the virus or been inoculated against it, their blood should contain antibodies that will latch onto proteins that appear naturally on a particular virus and exist in these antibody tests. While there are also tests for detecting other parts of the immune system, such as T cells, they're more expensive and are used less often.
The Reference Shelf
- Related QuickTakes on the omicron variant, Covid treatments and vaccine mandates.
- The FDA's statement about the effect of omicron on tests.
- Guidance on testing from the U.S. CDC and the FDA.
- The OECD's guidance on how to best use coronavirus tests.
- Bloomberg's Virus Tracker monitors the state of the pandemic.
©2022 Bloomberg L.P.
-
India's Troika Of Good Luck | Joining The Dots
A weaker Trump, a cooling AI trade and resilient earnings have put Indian markets back in favour. Rising inflation could spoil the party.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.